- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01537822
The Hysteroscopic Morcellator (HM). (HM)
The Hysteroscopic Morcellator Versus the Bipolar Resectoscope for Removal of Lager Intrauterine Polyps, Removal of Submucous Myomas and Removal of Residual Placental Tissue: a Randomized Controlled Trial.
Rationale:
The hysteroscopic morcellator (HM) is a novel technique for removal of intrauterine polyps, myomas and placental tissue. It withholds some technical advantages over resectoscopy. Previous data suggest that it's a faster technique than the latter, and shows that it has a low complication rate.
Objective:
To compare the HM to bipolar resectoscopy for removal of:
1) large intrauterine polyps, 2) smaller type 0 and 1 myomas, 3) residual placental tissue, in terms of efficiency and complications.
Study design: Single blind, randomized controlled multicenter trial.
Study population: Women aged over 18 years old with:
1) large (≥ 1 cm) intrauterine polyps, 2) smaller (≤ 3 cm) type 0 or 1 myomas, 3) residual placental tissue, who are planned for hysteroscopic removal.
Intervention:
Patients are randomized between removal with the HM or the bipolar resectoscope.
Main study parameters/endpoints:
Installation and operating time.
Nature and extent of the burden and risks associated with participation, benefit and group relatedness:
Women who are referred to our polyclinic will be seen on a first visit, and, according to the standard work-up, an ultrasound will be performed when intrauterine pathology is suspected. To confirm the diagnosis a saline infusion sonography (SIS) and/or ambulant diagnostic hysteroscopy will be performed consequently. Once the diagnosis is confirmed and surgery is planned, women will be asked whether they want to take part in this study. At this moment, both techniques are used in our hospitals and the choice of treatment depends on the preference of the gynaecologist. All women will be treated with operative hysteroscopy in a daycare setting according to the standard of care, only now randomized between the two techniques. A standard postoperative visit with ultrasound examination and/or ambulant diagnostic hysteroscopy is scheduled 6 weeks later. Late postoperative complications and complaints are recorded.
It is expected that the HM beholds some advantages over the bipolar resectoscope such as shorter operating time and less complications (e.g. risk of perforation, current and fluid related complications). Previous data do not demonstrate any additional risks related to the use of the HM. Moreover we will check whether the HM has a lower risk of intrauterine adhesion formation, as this might influence patient's fertility.
After completion of the RCT, an observational study is planned considering pregnancies subsequent to the hysteroscopic procedure.
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Ghent, Belgium, 9000
- Ghent University Hospital
-
-
-
-
-
Eindhoven, Netherlands, 5602 ZA
- Catharina Hospital Eindhoven
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients with one or more intrauterine polyp(s) with a diameter ≥ 1 cm as seen on ultrasound, confirmed by saline infusion sonography and/or ambulant diagnostic hysteroscopy who are planned for hysteroscopic surgery.
- Patients with one or more intrauterine myoma(s) with a diameter ≤ 3 cm as seen on ultrasound, confirmed by saline infusion sonography and/or ambulant diagnostic hysteroscopy who are planned for hysteroscopic surgery.
- Patients with residual placental tissue as seen by ambulant diagnostic hysteroscopy who are planned for hysteroscopic surgery.
Exclusion Criteria:
- Only polyps < 1cm (Note: intrauterine polyps < 1 cm are treated in an ambulatory setting).
- Myomas with a diameter > 3 cm (Note: Myomas > 3 cm are treated with resectoscopy)
- Type 2 myomas
- Visual or pathological (e.g. on biopsy) evidence of malignancy preoperatively or at the time of operation.
- Untreated cervical stenosis making safe access for operative hysteroscopy impossible as diagnosed preoperatively or at the time of operation.
- With a contra-indication for operative hysteroscopy.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: hysteroscopic morcellator
Women, randomized into getting a treatment with the hysteroscopic morcellator.
|
Morcellation will be performed with the HM (TRUCLEAR, Smith & Nephew, Andover, USA).
The rotary blade is used for polypectomy and removal of residual placental tissue; the reciprocating blade is used for myomectomy.
The blade has a window-opening at the end with cutting edges through which tissue is aspirated by means of a vacuum source.
The removed tissue is discharged through the device, collected in a pouch and made available for pathology analysis.
|
Active Comparator: Resectoscope
Women, randomized into getting a treatment with the resectoscope.
|
Resectoscopy will be performed with a rigid 8.5 mm bipolar resectoscope (Karl Storz GmbH, Tuttlingen, Germany), equipped with a 0 or 30 degree optic.
Normal saline is used for distension and irrigation of the uterine cavity.
Fluid balance is closely monitored using a Hystero pump (Richard Wolf GmbH, Knittlingen, Germany) or Hysteromat pump (Karl Storz GmbH, Tuttlingen, Germany).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Installation time and operating time.
Time Frame: the length of the operation
|
Installation time is defined as the time to set up the hysteroscopic instrumentation ready for use (time from start of setting up the instrumentation to start resection / morcellation). Operating time is defined as the time starting visual introduction of the hysteroscope until the time at which the procedure is completed and the hysteroscope is removed definitely. Times will be measured with a stop watch by a trained nurse. |
the length of the operation
|
Check for adhesions during follow-up.
Time Frame: After 6 weeks, during follow-up visit
|
Ambulant diagnostic hysteroscopy is performed at 6 weeks postoperative follow-up.
|
After 6 weeks, during follow-up visit
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Fluid deficit
Time Frame: during the length of the operation
|
Fluid deficit in both procedures is the result of subtracting the outflow volumes from the inflow volumes as measured by the pump.
|
during the length of the operation
|
complications and complaints
Time Frame: between operation until 6 weeks follow-up
|
During the postoperative hospital stay blood samples looking for electrolyte imbalances will only be taken when excessive fluid absorption is suspected based on fluid deficit (> 2500 mL for normal saline) and/or clinical symptoms. At 6 weeks postoperatively a standard visit is scheduled. Complications and complaints are recorded, and ultrasound is performed. |
between operation until 6 weeks follow-up
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pregnancy rate
Time Frame: between the hysteroscopic removal of residual placental tissue and the first clinical pregnancy up to 7 years of follow-up
|
number of pregnancies / number of women wishing to conceive
|
between the hysteroscopic removal of residual placental tissue and the first clinical pregnancy up to 7 years of follow-up
|
Pregnancy outcome
Time Frame: the first pregnancy subsequent to the hysteroscopic removal of residual placental tissue up to 7 years of follow-up
|
Pregnancy outcome (biochemical / EUG / miscarriage / fetal demise / live birth)
|
the first pregnancy subsequent to the hysteroscopic removal of residual placental tissue up to 7 years of follow-up
|
Pregnancy complication
Time Frame: the first pregnancy subsequent to the hysteroscopic removal of residual placental tissue up to 7 years of follow-up
|
Pregnancy complication (vaginal blood loss / preterm contractions / PPROM / pregnancy induced hypertension / preeclampsia / eclampsia / uterine rupture)
|
the first pregnancy subsequent to the hysteroscopic removal of residual placental tissue up to 7 years of follow-up
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Steven Weyers, MD, PhD, University Hospital, Ghent
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2011/679
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Large Intrauterine Polyps
-
Catholic University of the Sacred HeartCompleted
-
Washington University School of MedicineCompletedBenign Polyps of Large IntestineUnited States
-
Professor Michael BourkeCompletedAdenomatous Polyp of Large IntestineAustralia
-
Medical University of ViennaCompletedMultiple Polyps Right Colon | Large Polyp Right Colon | Suspected Polyp Right ColonAustria
-
Johns Hopkins UniversityCompletedLarge Polyps in the Gastrointestinal TractUnited States
-
Radboud University Medical CenterRecruiting
-
Bo-In LeeSt Vincent's Hospital; Incheon St.Mary's HospitalCompletedPolyp of Large IntestineKorea, Republic of
-
Creo Medical LimitedSt Mark's Hospital, Harrow, UKCompleted
-
Asan Medical CenterCompleted
-
Istituto Clinico HumanitasSan Gerardo Hospital; Azienda Ospedaliero Universitaria Maggiore della CaritaCompletedBleeding | Colonic Polyps | Complications | Polyp of Large Intestine | Colon Nos Polypectomy Tubular AdenomaItaly
Clinical Trials on Hysteroscopic morcellator
-
Hologic, Inc.CompletedInfertility | Abnormal Uterine Bleeding
-
Hologic, Inc.CompletedPolyps | Uterine FibroidsUnited States
-
Indiana Kidney Stone InstituteRichard Wolf Medical Instruments Corporation (RWMIC)CompletedBenign Prostatic Hypertrophy Requiring Surgical InterventionUnited States
-
Birmingham Women's NHS Foundation TrustSmith & Nephew, Inc.CompletedEndometrial PolypsUnited Kingdom
-
University Hospital, Strasbourg, FranceCompletedEndometrial PolypsFrance
-
Olympus Surgical Technologies EuropeWithdrawn
-
Far Eastern Memorial HospitalRecruitingHysteroscopic MyomectomyTaiwan
-
Brugmann University HospitalWithdrawnSymptomatic Submucosal MyomaBelgium, France
-
Shanghai First Maternity and Infant HospitalUnknownCesarean Section ScarChina